Doctor Alberto Cordero

Doctor Alberto Cordero

Hospital San Juan de Alicante, Alicante (Spain)

Member of:

Interventional cardiologist involved in cardiovascular prevention and treatment. Research on acute coronary syndromes, secondary prevention and lipids.

Presentations Articles

Decision support system for risk stratification in patients with heart failure referred to Cardiology.

Event: ESC Congress 2025

Topic: Disease Classification

Session: Personalised medicine: risk stratification through digital health tools

Access

Lipid profile risk in menopausal women with no significant increase in lipoprotein(a)

Event: ESC Congress 2025

Topic: Biomarkers

Session: Risk factors: biomarkers

Access

Identification of patients eligible for treatment with semaglutide after an acute coronary syndrome according to guidelines recommendations

Event: ESC Congress 2025

Topic: Obesity

Session: Challenges of managing obesity in cardiovascular disease

Access

Trends in the gender-gap of cardiovascular disease mortality in Spain in the last 2 decades

Event: ESC Congress 2025

Topic: Cardiovascular Epidemiology

Session: From population studies to patient care: the role of epidemiology in cardiology

Access

Effect of triglycerides on cardiovascular risk in patients with a first vs. recurrent acute coronary syndrome

Event: ESC Congress 2024

Topic: Lipids

Session: Lipids in heart disease

Access

Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome

Event: ESC Congress 2024

Topic: Drug therapy

Session: Lipids in heart disease

Access

The determinant role of high-density lipoprotein cholesterol on the recovery of left ventricle ejection fraction after acute coronary syndromes

Event: ESC Congress 2023

Topic: Lipids

Session: Risk factors and prevention: lipids (4)

Access

HDLc levels have a protective effect for in-hospital mortality in Non-STEMI but not in STEMI patients.

Event: ESC Congress 2023

Topic: Lipids

Session: Risk factors and prevention: lipids (3)

Access

The real-world cost and health resource utilization associated to the CNIC-polypill containing Atorvastatin 20mg in secondary prevention patients: a subanalysis of the NEPTUNO study

Event: ESC Preventive Cardiology 2023

Topic: Public Health and Health Economics, Other

Session: Late-Breaking Science session

Access

We need a generalised approach to improve impact at the population level

Event: ESC Preventive Cardiology 2023

Topic: Secondary Prevention

Session: Managing cardiovascular risk: precision medicine for the individual patient or a better generalised approach at the population level?

Access

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Doctor Alberto Cordero

Biography

Contributor content

Decision support system for risk stratification in patients with heart failure referred to Cardiology.

Lipid profile risk in menopausal women with no significant increase in lipoprotein(a)

Identification of patients eligible for treatment with semaglutide after an acute coronary syndrome according to guidelines recommendations

Trends in the gender-gap of cardiovascular disease mortality in Spain in the last 2 decades

Effect of triglycerides on cardiovascular risk in patients with a first vs. recurrent acute coronary syndrome

Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome

The determinant role of high-density lipoprotein cholesterol on the recovery of left ventricle ejection fraction after acute coronary syndromes

HDLc levels have a protective effect for in-hospital mortality in Non-STEMI but not in STEMI patients.

The real-world cost and health resource utilization associated to the CNIC-polypill containing Atorvastatin 20mg in secondary prevention patients: a subanalysis of the NEPTUNO study

We need a generalised approach to improve impact at the population level

ESC 365 is supported by

Doctor Alberto Cordero Follow

Biography

Contributor content

Decision support system for risk stratification in patients with heart failure referred to Cardiology.

Lipid profile risk in menopausal women with no significant increase in lipoprotein(a)

Identification of patients eligible for treatment with semaglutide after an acute coronary syndrome according to guidelines recommendations

Trends in the gender-gap of cardiovascular disease mortality in Spain in the last 2 decades

Effect of triglycerides on cardiovascular risk in patients with a first vs. recurrent acute coronary syndrome

Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome

The determinant role of high-density lipoprotein cholesterol on the recovery of left ventricle ejection fraction after acute coronary syndromes

HDLc levels have a protective effect for in-hospital mortality in Non-STEMI but not in STEMI patients.

The real-world cost and health resource utilization associated to the CNIC-polypill containing Atorvastatin 20mg in secondary prevention patients: a subanalysis of the NEPTUNO study

We need a generalised approach to improve impact at the population level

ESC 365 is supported by

Doctor Alberto Cordero